Huons Global plans to launch a new botulinum toxin (BTX) product in Korea.

Liztox, developed by Huons Global, is a BTX type A, indicated for treating forehead wrinkles. The company completed relevant clinical trials and received sales approval from the Ministry of Food and Drug Safety in April.

"Huons Global plans to use the group's resources to become a game changer in the BTX market," the company said. To this end, the company has established a two-track strategy with its two subsidiaries -- Huons, a pharmaceutical company, and Humedix, an aesthetic unit.

Huons said it would focus on the growth of the botulinum toxin market domestically and internationally, and Humedix will concentrate on the domestic aesthetic market.

Huons is also accelerating local licensing and clinical trials in Europe, China and Latin American countries that have signed an agreement with it, and is in the process signing contracts with major countries, including the U.S.

Locally, the company plans to expand the BTX market by using the company's know-how and network.

"The launch of Liztox, which will lead the growth of the Huons Group, has been confirmed in Korea," Huons Global CEO Kim Wan-seop said. "We will use every aspect of the group to launch the product in the local market successfully."